News & Updates

Long-term treatment with dupilumab is well tolerated, and its efficacy in children with uncontrolled, moderate-to-severe asthma as seen in the VOYAGE study is consistent, according to the EXCURSION open-label extension study. In addition, patients who switched from placebo to dupilumab has improved rapid lung function.

Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.

A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.

A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.

Maintenance treatment with 5-aminosalicylates (5-ASA) in patients with newly diagnosed Crohn's disease (CD) does not appear to lead to better outcomes as compared with a watchful waiting approach, according to a study.